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Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of
the most common types of human cancer, with an annual inci-
dence of more than 500,000 cases worldwide. In the United
States alone, approximately 28,000 men and 12,000 women
are diagnosed with HNSCC each year, representing 3.2% of all
newly diagnosed cancers; the disease also accounts for 2.1% of
cancer-related deaths in the United States (Jemal et al., 2004).
HNSCC is associated with severe disease- and treatment-relat-
ed morbidity and has a 5-year survival rate of approximately
50%; this rate has not improved in more than 2 decades
(Forastiere et al., 2001).
HNSCC is a complex disease arising in various organs,
including the oral cavity, pharynx, and larynx. Tumors from
these different sites have distinct clinical presentations and clin-
ical outcomes, and are treated with different strategies, which
may include surgery, radiotherapy, and chemotherapy. Recent
molecular studies have advanced our understanding of the dis-
ease and provided a rationale to develop novel strategies for its
early detection, classification, prevention, and treatment.
Tobacco use and alcohol intake are the major risk factors for
development of HNSCC (Decker and Goldstein, 1982).
However, the exact mechanisms by which tobacco carcinogens
and alcohol induce transformation and malignant progression of
epithelial cells in the head and neck are not fully understood.
The fact that most tobacco and alcohol users do not develop
HNSCC in their lifetimes and that approximately 20% of patients
with HNSCC, particularly female and those with younger ages,
have no clear evidence of exposure to the common risk factors
underscores the complexity of HNSCC tumorigenesis and the
important role of gene-environment interactions in the tumori-
genic process.
Like most epithelial cancers, HNSCC develops through the
accumulation of multiple genetic and epigenetic alterations in a
multistep process (Figure 1). Deletion of tumor suppressor
regions, mutations and de novo promoter methylation of tumor
suppressor genes, and amplification or overexpression of onco-
genes have been frequently detected in HNSCC. Many of these
alterations occur early in tumorigenesis and are identified in
premalignant lesions of the head and neck—and even in histo-
logically normal tissues—that are chronically exposed to com-
mon carcinogens. Further understanding of the molecular
process behind HNSCC tumorigenesis will be essential for the
development of novel strategies for early diagnosis and cancer
risk assessment, molecular classification, and targeted preven-
tion and treatment (Figure 1).
Etiology
Through a large number of epidemiologic studies, a strong link
has been established between the use of tobacco and an
increased risk for HNSCC. Alcohol is another independent risk
factor for the disease that may have a synergistic effect when
combined with tobacco. The risk for development of oral cancer
is 3 to 9 times greater in those who smoke or drink and as much
as 100 times greater in those who both smoke and drink heavily
than in those who neither smoke nor drink (Neville and Day,
2002). Mutations of p53 have been found more frequently in the
HNSCC of smokers and drinkers than in those of other patients
(Brennan et al., 1995), suggesting that inactivation of the p53
tumor suppressor gene is important in tobacco- (and possibly
alcohol-) induced HNSCC tumorigenesis.
Human papillomavirus (HPV) may play an important role in
the etiology of HNSCC, particularly for tumors of the oro-
pharynx (Gillison et al., 2000). The E6 protein found in the
oncogenic high-risk types of HPV, such as HPV-16, can bind to
the p53 protein and accelerate its degradation, thereby limiting
its ability to inhibit growth of, induce apoptosis in, or cause sub-
stantial genetic damage to cancer cells.Thus, it is not surprising
that HNSCC with p53 mutations rarely carry HPV, while oropha-
ryngeal tumors with E6-protein expression lack p53 mutations
(Gillison et al., 2000; Mork et al., 2001), supporting the role of
HPV in the development of a subset of HNSCC.
Other risk factors for HNSCC include poor hygiene in the
oral cavity; environmental contaminants such as paint fumes,
plastic byproducts, and gasoline fumes; gastroesophageal
reflux disease; dietary factors; and use of marijuana. In patients
with HNSCC who lack clear exposure to the common risk fac-
tors, the identification of the etiology of HNSCC will be critical to
develop strategies to prevent and treat the disease.
Histologic and clinical classification
HNSCC is graded histologically as well, moderately, or poorly
differentiated carcinoma. Well-differentiated tumors contain
orderly stratification and heavy keratinization in a pear forma-
tion. Moderately differentiated tumors have prickle cells, some
stratification, and less keratinization. Poorly differentiated
tumors are still recognizable as squamous cell carcinomas but
manifest prominent nuclear pleomorphisms and atypical mito-
sis. However, although the histologic differentiation status is
required in pathology reports of HNSCC, it provides limited
information to guide treatment decisions because a strong
association between differentiation status and clinical outcome
or treatment response is lacking.
The anatomic location of HNSCC is important for their clini-
cal classification because tumors arising from different locations
often have distinct clinical outcomes and different functional con-
siderations. For example, tumors in the hypopharynx have a
higher probability of metastasizing compared to tumors in the
oral cavity or larynx. By contrast, laryngeal tumors metastasize
infrequently, and patients with these tumors often receive no or
minimal surgery but do receive chemoradiotherapy in order to
retain their speech function (Forastiere et al., 2003).
The TNM staging system is important in clinical practice to
guide treatment selection, and survival of HNSCC patients is
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strongly associated with TNM stage. The system is based on
tumor size and invasion features (T stage), regional lymph node
spread (N stage), and the presence of distant metastasis (M
stage). However, patients classified as having the same stage of
disease may differ substantially in their response to the same
treatment and in their clinical outcome, indicating the need for a
staging system based on molecular characteristics of the
tumors.
Molecular basis of HNSCC tumorigenesis
Deletion of one of the two alleles at chromosomes 3p (multiple
regions) and 9p21 is the most frequent event in lesions of the
head and neck with only mild histologic changes, such as
hyperplasia and mild dysplasia, and even in some normal-
appearing epithelial cells (Mao et al., 1996a). Because these
chromosomal regions harbor tumor suppressor genes, such as
FHIT at 3p14 and p16INK4a at 9p21, such deletions might affect
malignant transformation. This theory is supported by the
observation that the lesions of oral leukoplakia with deletions at
3p14 and 9p21 carry a higher risk for transformation into inva-
sive tumors (Mao et al., 1996a; Rosin et al., 2000). Oral leuko-
plakia is the most common head and neck premalignant lesion
and has a malignant transformation rate as high as 24%
(Papadimitrakopoulou et al., 1997). However, our ability to pre-
dict the malignant potential of these lesions based on patholog-
ic findings is very limited. Given the identification of multiple
molecular alterations in these lesions, molecular markers may
have promise in improving our ability to determine the true can-
cer risk of these lesions. Another important event in the early
tumorigenic process of HNSCC is the reactivation of telomerase
(Mao et al., 1996b; Mutirangura et al., 1996) prolonging survival
of cells with genetic abnormalities and making accumulation of
multiple genetic alterations possible. Califano et al. analyzed
head and neck lesions at various stages of tumorigenesis to
detect deletions at multiple chromosomal regions and proposed
a progression model (Califano et al., 1996).
The p53 tumor suppressor gene is the most frequently
mutated gene in HNSCC, with a frequency close to 50%
(Brennan et al., 1995). Inactivation of p53 makes HNSCC more
resistant to radiotherapy and oral premalignancies less sensi-
tive to retinoid-based chemopreventive strategies (Koch et al.,
1996; Shin et al., 2000). Gene amplification and protein overex-
pression have been found in HNSCC. The gene cyclin D1, for
example, is frequently amplified and overexpressed in early
stage head and neck tumorigenesis (Izzo et al., 2003).
Overexpression of epidermal growth factor receptor (EGFR) is
an important feature in HNSCC and has been the basis for tar-
geting EGFR as a treatment strategy (Pomerantz and Grandis,
2003). p63, a p53 homolog with oncogenic property, is also fre-
quently amplified and overexpressed in HNSCC (Patturajan et
al., 2002).
Silencing gene expression by hypermethylation of CpG-rich
promoters is a common mechanism to inactivate tumor sup-
pressor genes in many types of cancers, such as p16, DAP-
kinase, and E-cadherin in HNSCC (Herman and Baylin, 2003;
Hasegawa et al., 2002). Aberrant pre-mRNA splicing is another
epigenetic mechanism that may inactivate tumor suppressor
genes and generate oncogenes (Bartel et al., 2002). We have
shown that this may be an important mechanism to inactivate
FHIT in HNSCC (Mao et al., 1996c).
Many of these molecular abnormalities, particularly DNA
deletions and amplifications, are the consequence of genomic
instability. Recent studies have shown that genomic instability
(aneuploidy) is critical in oral cancer development (Sudbo et al.,
2001) and that patients whose tumors developed from aneu-
ploidy lesions had extremely poor clinical outcomes (Sudbo et
al., 2004). Understanding the mechanism for genomic instability
may lead to novel preventive or therapeutic strategies prevent-
ing or minimizing genomic instability.
Field cancerization and development of multiple tumors
The concept of field cancerization was introduced to explain
how multiple primary tumors develop in the upper aerodigestive
tract, based on the fact that the entire tract is chronically
exposed to common carcinogens, such as tobacco smoke
(Slaughter et al., 1953). The concept has been challenged
because some clinically diagnosed second primary tumors dis-
tant from the original tumor appeared to derive from clonal
spreading of the original one based on genetic analysis (Bedi et
al., 1996). In a recent study, we showed that clonal spreading
occurred in invasive and noninvasive lesions, although the
probability of clonal spreading increased with tumor progres-
sion. However, we also found that other multiple oral lesions
developed independently, supporting a strong role for field can-
cerization (Jang et al., 2001). Figure 2 shows the location of a
patient’s multiple oral lesions that developed over a 10-year
period to illustrate the effect of carcinogen-induced field cancer-
ization and clonal spreading based on molecular analysis.
Prevention
The development of HNSCC requires accumulation of genetic
and epigenetic alterations, and thus can theoretically be inter-
rupted, delayed, or reversed through the use of natural or syn-
thetic agents in a process known as chemoprevention (Hong
and Sporn, 1997).
High-dose retinoids have established efficacy in the rever-
sal of early oral premalignant lesions but are associated with
mucocutaneous toxicity (Hong et al., 1986). The efficacy of
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Figure 1. Multistep process and field effect in HNSCC tumorigenesis
Chronic exposure to tobacco carcinogens in the upper aerodigestive
tract causes genetic and epigenetic damage in epithelial cells.
Accumulation of this damage leads to the development of premalignant
lesions and invasive cancers. Understanding the common genetic and
epigenetic alterations that are important in the tumorigenic process is criti-
cal in the development of molecularly based management strategies.
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retinoids on moderately and severely dysplastic lesions were
addressed with a combination of interferon-α, α-tocopherol,
and 13-cis-retinoic acid (Papadimitrakopoulou et al., 1999). The
study revealed the activity of this combination in reversing his-
tology of laryngeal lesions but with persistence of genetic
abnormalities in the tissue despite histologic response (Mao et
al., 1998). A phase II trial showed that the same combination of
drugs was highly effective as bioadjuvant therapy in patients
previously treated for a locally advanced head and neck cancer
(Shin et al., 2001).
The possibility of preventing second primary tumors was
suggested by a randomized, double-blinded, placebo-controlled
trial of high-dose 13-cis-retinoic acid taken for 1 year by patients
whose original HNSCC were curatively treated (Hong et al.,
1990). However, these results were not confirmed by studies
with low-dose 13-cis-retinoic acid (Khuri et al., 2003) or with dif-
ferent retinoids (van Zandwijk et al., 2000).
New strategies in chemoprevention include targeting p53
abnormalities, selective cyclooxygenase-2 inhibitors, EGFR
kinase inhibitors, and the epigallocatechin gallate component of
green tea. Newer studies should be designed to treat lesions
with a higher genetically defined risk for cancer development,
such as aneuploidy or loss of heterozygosity at specific tumor
suppressor loci in oral premalignant lesions (Sudbo et al., 2001;
Mao et al., 1996b; Partridge et al., 2000; Rosin et al., 2000) or
patients with certain cyclin D1 polymorphisms (Izzo et al., 2003).
Current treatment of head and neck cancer
Advances have occurred in all major treatments for HNSCC,
including surgery, radiotherapy, chemotherapy, and use of tar-
geted therapeutic agents. The focus of surgical innovation dur-
ing the past decade has been the conservation of organ
function and more effective means of reconstruction. Advances
in radiotherapy approaches have involved dividing the dose of
radiotherapy to increase its efficacy, including hyperfractiona-
tion and accelerated fractionation. Phase III trials testing both of
these approaches have documented that they result in a 10% to
15% improvement in local and regional tumor control in patients
with middle-stage to advanced-stage disease, although without
a significant change in the overall survival rate (Fu et al., 2000;
Horiot et al., 1997).
In the past several years, new treatment strategies have
incorporated chemotherapy as an integral component of poten-
tially curative therapy aimed at organ preservation, optimal dis-
ease control, and prolongation of survival time.
In the late 1980s to mid-1990s, induction chemotherapy fol-
lowed by radiotherapy achieved the goal of laryngeal preserva-
tion, as demonstrated by the Veterans Administration Laryngeal
Cancer Study and the similarly designed trial of the European
Organization for Research and Treatment of Cancer, for
hypopharyngeal cancer, with equivalent survival for patients
treated with induction chemotherapy followed by radiotherapy to
that of patients treated with standard surgical resection followed
by postoperative radiation (Department of Veterans Affairs
Laryngeal Cancer Study Group, 1991; Lefebvre et al., 1996).
Over the past 10 years, the simultaneous administration of
chemotherapy and radiotherapy has become the subject of
intense clinical research. The rationale for this approach lies in
its potential to overcome radioresistance within the irradiated
field, to eradicate micrometastatic disease, to target different
cell subpopulations within the tumor, to enable chemotherapy-
associated inhibition of repair of DNA damage induced by
radiation, and to cause cell cycle redistribution toward more
radiosensitive phases.
A meta-analysis that included 63 randomized studies con-
ducted between 1965 and 1993 showed an absolute survival
benefit of 4% at 5 years with the addition of chemotherapy to
locoregional treatment. The survival benefit was confined to tri-
als that compared concomitant chemoradiotherapy with radio-
therapy alone (absolute survival benefit for chemoradiotherapy,
8% at 5 years) (Pignon et al., 2000). Recent phase III studies
have almost uniformly supported the superiority of concurrent
chemoradiotherapy over radiation alone in the setting of unre-
sectable HNSCC (Forastiere et al., 2001), in terms of either sur-
vival (Adelstein et al., 2003; Jeremic et al., 2000) or organ
preservation (Forastiere et al., 2003).
The potential advantages of using multiagent chemoradio-
therapy have been investigated in several phase II or III trials.
Satisfactory results have been reported in phase II trials with
the combination of radiation, 5-fluorouracil, and hydroxyurea
(Kies et al., 2001; Vokes et al., 2000). A recent phase II random-
ized study was conducted by the Radiation Therapy Oncology
Group (RTOG 9703) to compare three doublet chemotherapy
regimens (cisplatin and 5-fluorouracil, hydroxyurea and 5-fluo-
rouracil, and cisplatin and paclitaxel) administered with conven-
tional radiotherapy (Garden et al., 2001). Although no
statistically significant difference in survival rate was shown
among three arms, all had superior survival rates compared
with historical radiation-alone data from the RTOG. Further ran-
domized studies are needed to establish the optimal combina-
tion regimen for chemoradiotherapy programs.
Based on these data, the standard nonsurgical therapy for
patients with HNSCC should involve combined radiation and
chemotherapy, given concurrently. The optimal chemotherapy
regimen and fractionation scheme and the role of induction and
adjuvant chemotherapy still remain to be defined.
Given the locoregional pattern of treatment failure in
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Figure 2. Field cancerization versus clonal spread
The diagram shows the sites of 14 oral lesions that developed in a patient
over 10 years. There were nine invasive cancers and five premalignant
lesions. Each lesion was treated by complete resection at the time of diag-
nosis. Each lesion is numbered according to the sequence of diagnosis.
Lesions with the same color shared identical genetic alterations, suggest-
ing the same clonal origin based on results of genetic analysis and a math-
ematic model. Four independent clones might have been responsible for
the development of all 14 oral lesions in this patient.
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HNSCC and the ominous prognosis for patients with HNSCC
who are not candidates for surgery (Vokes et al., 1993), the use
of concomitant reirradiation and chemotherapy in such patients
is currently under investigation by multiple clinical trial groups,
with encouraging preliminary data, especially following surgical
debulking (De Crevoisier et al., 2001).
In the setting of recurrent and metastatic disease, single
agents with activity in the range of 15% to 30% include
methotrexate, cisplatin, carboplatin, 5-fluorouracil, paclitaxel,
and docetaxel. Combination chemotherapy has been shown to
result in significantly higher response rates than those achieved
by single-agent chemotherapy.The combination of cisplatin and
5-fluorouracil given by continuous intravenous infusion is the
most frequently used regimen (Forastiere et al., 2001), although
it has resulted in no improvement in the median duration of sur-
vival of 6 months or in the overall survival rates. Similarly, ran-
domized trials directly comparing newer regimens, such as
paclitaxel or docetaxel plus cisplatin or carboplatin, with the
standard cisplatin and 5-fluorouracil regimen have not shown
superiority in terms of survival rate.
Targeted therapies for head and neck cancer
Development of new agents to treat HNSCC has mainly con-
centrated on recurrent and metastatic disease, for which no
effective chemotherapy is currently available. These new drugs,
designed to target specific molecular defects unique to cancer
cells (Figure 3), include EGFR inhibitors, tyrosine kinase
inhibitors, protein farnesylation inhibitors, and p53-replacing
therapy.
EGFR overexpression occurs in head and neck premalig-
nant and malignant lesions with a frequency of 80% to 100%
and is generally associated with an adverse outcome (Grandis
et al., 1998). EGFR is a member of the ErbB receptor tyrosine
kinase family; its ligands epidermal growth factor and transform-
ing growth factor-α cause receptor dimerization, and activation
of receptor tyrosine kinase and phosphorylation of several sub-
strates result in activation of signal transduction pathways (e.g.,
the ras/mitogen-activated protein kinase, phosphatidylinositol-3
kinase, and signal transducer and activator of transcription-3
pathways) that can lead to cell proliferation, tumor growth, and
progression of invasion and metastasis (Salomon et al., 1995).
Many strategies to block or downregulate the EGFR have
been developed, including the use of tyrosine kinase inhibitors,
monoclonal antibodies, ligand-linked toxins, and antisense
oligonucleotides (Mendelsohn and Baselga, 2003). The cellular
effects of EGFR blockade include cell cycle arrest, potentiation
of apoptosis, inhibition of angiogenesis, and inhibition of tumor-
cell invasion and metastasis. Enhanced cytotoxicity has been
observed when the monoclonal antibody against the EGFR,
cetuximab, is used in combination with a number of convention-
al cytotoxic therapies plus radiotherapy; this combination works
by inhibiting tumor cell repopulation. Cetuximab has also been
shown to cause response in 10%–14% of platinum-resistant
HNSCC when the antibody was added to a regimen of cisplatin
or carboplatin after documented progression of disease
(Mendelsohn and Baselga, 2003). However, a randomized clini-
cal trial comparing cisplatin in combination with cetuximab or
placebo revealed no statistically significant difference in terms
of progression-free survival, despite a higher response rate in
the group receiving cetuximab. A phase III randomized trial
attempting to confirm the effectiveness of cetuximab in combi-
nation with radiotherapy is being evaluated (Mendelsohn and
Baselga, 2003).
Reversible and irreversible small molecule tyrosine kinase
inhibitors have shown preclinical activity with good bioavailabili-
ty and have moved into clinical trials, both alone and in combi-
nation with chemotherapy. ZD1839 (Iressa, or gefitinib) and
OSI-774 (Tarceva, or erlotinib) are reversible tyrosine kinase
inhibitors that have demonstrated promising antitumor activity in
early clinical trials conducted mainly in patients with advanced
non-small cell lung cancer. Major side effects include mild acne-
like rash, diarrhea, and nausea. Phase II studies of both com-
pounds have been completed in patients with recurrent and
metastatic HNSCC, resulting in response rates of 10% for gefi-
tinib and 4% for erlotinib (Cohen et al., 2003; Soulieres et al.,
2004). Ongoing studies in HNSCC are exploring combinations
of oral tyrosine kinase inhibitors with radiotherapy and cisplatin.
Approximately 90% of human neoplasms have abnormali-
ties in some component critical for the G1 to S phase cell cycle
transition. In HNSCC, cyclin D1 is commonly overexpressed,
and p16, the endogenous inhibitor of cyclin-dependent kinase-4,
is commonly deleted or not transcribed. Flavopiridol is a pharma-
cologically potent cyclin-dependent kinase inhibitor that depletes
cyclin D1 and vascular endothelial growth factor mRNA, induces
apoptosis, and suppresses the growth of HNSCC. This drug has
been tested in clinical trials in patients with HNSCC (Patel et al.,
1998); the optimal schedule and combination with standard cyto-
toxic agents are still being investigated.
The initial premise behind developing farnesyl transferase
inhibitors was to inhibit a critical enzymatic activity for the con-
stitutive function of mutated Ras (Lebowitz et al., 1995).
However, in preclinical and clinical settings, these compounds
appeared to inhibit tumor growth irrespective of their Ras status.
A phase IB trial of the farnesyl transferase inhibitor SCH66336
in HNSCC has observed substantial reductions in tumor size,
despite short exposure to the drug. A phase II monotherapy trial
in recurrent, metastatic HNSCC is ongoing.
Replication-competent adenoviruses that selectively repli-
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Figure 3. Simplified scheme of the molecular abnormalities within signal
transduction pathways in HNSCC that are possible targets for intervention
with targeted therapies
C225, cetuximab; IGF, insulin-like growth factor; Abs, antibodies; RTKIs,
receptor tyrosine kinase inhibitors; FTI, farnesyl transferase inhibitors; Cdk,
cyclin-dependent kinase.
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cate in and cause lysis of cells deficient in p53 tumor suppres-
sor activity have been developed. Phase I and II clinical trials of
the intralesional injection of ONYX-015 in patients with recur-
rent or refractory HNSCC suggest that the adenovirus is effec-
tive and that the responses at injected tumor sites are durable
(Khuri et al., 2000). Replacement of the p53 gene using an ade-
novirus containing the wild-type p53 gene (Ad-p53 or RPR-
INGN-201) has been evaluated in a phase I trial in patients with
advanced, recurrent HNSCC and has led to some durable
responses and to a pathologic complete response (Clayman et
al., 1998). Based on these promising initial data, two ongoing
trials are testing the combination of Ad-p53, cisplatin, and 5-flu-
orouracil versus cisplatin and 5-fluorouracil alone and testing
Ad-p53 versus methotrexate as a second-line therapy in
patients with recurrent or metastatic HNSCC.
Some additional targets worthy of exploration in HNSCC for
which either small molecules or antibodies are in clinical devel-
opment are the mTOR inhibitors, insulin-like growth factor-sig-
naling blockers, histone deacetylase inhibitors, and heat shock
protein 90 inhibitors.
Conclusions
Progress in treatment of HNSCC has been slow and challeng-
ing. However, a number of studies have established the feasibil-
ity and efficacy of combining treatment modalities to enable
organ preservation and have laid the framework for circumven-
tion of the treatment plateau encountered with conventional
cytotoxic agents through the integration of molecularly targeted
agents. The challenges that lie ahead include determining the
optimal dose and sequence of these agents, the choice of the
appropriate setting for using biologically active agents targeting
actions different pathways of tumor growth, and, most impor-
tant, the timely integration of laboratory-based studies and
molecular imaging into the development of new treatments.
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